.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A recent case report in Postgraduate Medicine underscores severe ivermectin neurotoxicity risks. A 73-year-old woman with metastatic breast cancer self-administered massive doses of the antiparasitic agent. She acted on health misinformation found online. Consequently, she arrived at the hospital with acute mental status changes and life-threatening complications. This incident reflects a growing trend where patients bypass evidence-based care for unproven \"miracle cures.\"
The patient presented with generalized seizures and respiratory failure. These symptoms typically occur when high drug concentrations overwhelm the blood-brain barrier. Specifically, ivermectin is usually excluded from the central nervous system by P-glycoprotein. However, massive doses saturate this efflux pump. Therefore, the drug binds to GABA-gated chloride channels in the brain. This leads to profound depression of the central nervous system. Because the patient required immediate intervention, the medical team initiated mechanical ventilation and anticonvulsant therapy.
Fortunately, the patient achieved a full neurological recovery within 48 hours. This rapid improvement occurred after the cessation of the drug and intensive supportive care. Nevertheless, the case serves as a stark warning. Clinicians must remain vigilant regarding unconventional exposures. Furthermore, they should actively counsel patients about the hazards of non-evidence-based treatments. Misinformation online often omits the narrow therapeutic index of such medications in off-label settings.
Digital platforms frequently promote ivermectin as an alternative cancer therapy despite a lack of human clinical trials. While some in vitro studies show anticancer activity, the required concentrations are toxic to humans. Moreover, self-administration lacks the safety guardrails of professional oversight. Consequently, oncology teams should prioritize open communication about supplementary therapies. By doing so, they can identify potential risks before they escalate into emergencies.
No, the FDA and major oncology bodies have not approved ivermectin for cancer. Currently, no robust clinical evidence supports its efficacy in treating human malignancies.
Normally, the blood-brain barrier keeps ivermectin out using P-glycoprotein pumps. High doses saturate these pumps, allowing the drug to enter the brain and cause seizures or coma.
Management is primarily supportive. This includes airway protection, intravenous fluids, and controlling seizures with benzodiazepines. Clinicians should also contact a poison control center for guidance.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Saperstein Y et al. Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report. Postgrad Med. 2026 May 22. doi: 10.1080/00325481.2026.2672183. PMID: 42170801.
U.S. Food and Drug Administration. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. FDA Consumer Updates. 2023.
American Cancer Society. Ivermectin and Cancer: Exploring the Evidence and Risks. American Cancer Society Resources. 2026.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A case of life-threatening neurotoxicity in a breast cancer patient highlights the dangers of off-label ivermectin use and the impact of online misinformati...
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
